InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
0
T+90 hit rate
25%
T+90 mean return
-2.7%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Belldegrun Arie, Director. Insider active across 5 companies, notably Allogene Therapeutics, Inc.. Aggregated, 18 disclosures have been logged. Split: 4 buys · 0 sell. Total volume traded: €3.4m. History available since 24 May 2021. The latest transaction was filed on 24 January 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations18 total
369,957 shares0Common StockSEC:0001737287-25-000005:0
105,263 sharesClass A Common StockSEC:0001127602-24-018717:0
344,828 shares@ US$2.9011.1% of flowCommon StockSEC:0001737287-24-000042:0
211,973 shares0Common StockSEC:0001593968-24-000194:0
1,282,976 shares0Common StockSEC:0001593968-23-000523:0
160,000 shares@ US$5.0094.8% of flowOrdinary SharesSEC:0001437749-22-022616:0
3,241 shares@ US$5.001.9% of flowOrdinary SharesSEC:0001437749-22-021777:0
70,921 shares0Class A Common StockSEC:0000899243-22-022286:0
4,710,120 shares0Common StockSEC:0001214659-22-004729:0
4,710,121 shares0Common StockSEC:0001214659-22-004613:0
155,039 shares@ US$12.600.56% mcap23.3% of flowCommon StockSEC:0001214659-22-000701
Ideal exit: 9 Oct 2022 (T+270)
155,039 shares@ US$12.600.25% mcap23.3% of flowCommon StockSEC:0001214659-22-000701:0
Ideal exit: 9 Oct 2022 (T+270)
3,241 shares@ US$5.000.0010% mcap50.0% of flowOrdinary SharesSEC:0001209191-21-039138:0
3,241 shares@ US$5.001.6% of flowOrdinary SharesSEC:0001209191-21-039138
379,066 shares@ US$18.220.82% mcap76.7% of flowCommon StockSEC:0001214659-21-005878:0
379,066 shares@ US$18.2276.7% of flowCommon StockSEC:0001214659-21-005878
1,448,062 sharesCommon StockSEC:0000914190-16-000517:0
Ideal exit: 8 Oct 2016 (T+270)
714,285 sharesCommon StockSEC:0000914190-16-000517:1
Ideal exit: 8 Oct 2016 (T+270)
18 of 18 declarations
About Belldegrun Arie
Arie Belldegrun is a Board Member at Allogene Therapeutics, Inc. and UroGen Pharma Ltd. He plays a key role in the governance of these biopharmaceutical companies, contributing to the definition of their strategy and guiding their research efforts. His expertise in biotechnology is a valuable asset.
